



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



35812

PATENT TRADEMARK OFFICE

Art Unit : 1615
Examiner : Simon J. Oh
Serial No. : 10/045,341
Filed : October 25, 2001
Inventors : Bradley Stuart Galer
Title : METHOD FOR TREATING
: NON-NEUROPATHIC PAIN

Docket: 1203-01

Confirmation No.: 3845
Dated: March 7, 2003

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 CFR 1.137(b)

RECEIVED

MAR 14 2003

OFFICE OF PETITIONS

Office of Petitions
Box DAC
Commissioner for Patents
Washington, DC 20231

Sir:

The above-identified application became abandoned for failure to file a timely and proper Request to Withdraw a Non-Publication Request after filing an application directed to the invention disclosed in the present application, under a multilateral international agreement. The date of abandonment is the day after the expiration of the forty-five (45) day period beginning on the date of filing of the foreign application, which date of filing was 23 October 2002. Accordingly, Applicant hereby petitions for revival of this application.

Submitted herewith are: the Petition fee for a small entity (\$650), a Request to Withdraw the Non-Publication Request in this application, an Amendment in response to an outstanding Office Action, and a Request for Extension of Time. Since this utility application was filed after June 8, 1995, no terminal disclaimer is required.

03/14/2003 AWONDAF1 00000076 10045341

01 FC:2453

650.00 0P

Applicants hereby state that the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

Respectfully submitted,

Guy T. Donatiello, Reg. No. 33,167
Attorney for Applicant

GTD:ms

Dated: March 7, 2003
Endo Pharmaceuticals Inc.
100 Painters Drive
Chadds Ford, PA 19317
(610) 558-9800

Enclosures:

PTO-2038 (\$650)
Request to Withdraw the Non-Publication Request

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

7 March 2003

Amy Donatelli